Notable Reporting: Pfizer Inc Institutional Investor Sentiment Up in 2016 Q2

November 24, 2016 - By Winifred Garcia   ·   0 Comments

Notable Reporting: Pfizer Inc Institutional Investor Sentiment  Up in  2016 Q2

Sentiment for Pfizer Inc (NYSE:PFE)

Pfizer Inc (NYSE:PFE) institutional sentiment increased to 1.18 in Q2 2016. Its up 0.15, from 1.03 in 2016Q1. The ratio is positive, as 805 funds increased or started new holdings, while 784 cut down and sold holdings in Pfizer Inc. The funds in our partner’s database now have: 4.15 billion shares, down from 4.40 billion shares in 2016Q1. Also, the number of funds holding Pfizer Inc in their top 10 holdings increased from 177 to 239 for an increase of 62. Sold All: 80 Reduced: 704 Increased: 678 New Position: 127.

Pfizer Inc. is a research-based global biopharmaceutical company. The company has a market cap of $189.76 billion. The Firm is engaged in discovering, developing and manufacturing of healthcare products. It has a 31.37 P/E ratio. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

The stock increased 0.29% or $0.09 on November 23, hitting $31.42. About 21.27M shares traded hands. Pfizer Inc. (NYSE:PFE) has declined 5.56% since April 22, 2016 and is downtrending. It has underperformed by 10.97% the S&P500.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on February, 7. They expect $0.50 earnings per share, down 5.66% or $0.03 from last year’s $0.53 per share. PFE’s profit will be $3.02B for 15.71 P/E if the $0.50 EPS becomes a reality. After $0.61 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -18.03% negative EPS growth.

According to Zacks Investment Research, “Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer’s Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.”

Northeast Financial Consultants Inc holds 26.73% of its portfolio in Pfizer Inc. for 1.51 million shares. Whitnell & Co. owns 1.75 million shares or 20.14% of their US portfolio. Moreover, Rotella Capital Management Inc. has 15.02% invested in the company for 6,274 shares. The Arkansas-based Foundation Resource Management Inc has invested 10.31% in the stock. New England Professional Planning Group Inc., a Rhode Island-based fund reported 236,821 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 insider buys, and 2 insider sales for $882,530 net activity.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Ratings analysis reveals 39% of Pfizer’s analysts are positive. Out of 18 Wall Street analysts rating Pfizer, 7 give it “Buy”, 0 “Sell” rating, while 11 recommend “Hold”. The lowest target is $34 while the high is $51. The stock’s average target of $39.29 is 25.05% above today’s ($31.42) share price. PFE was included in 38 notes of analysts from July 29, 2015. The stock of Pfizer Inc. (NYSE:PFE) earned “Hold” rating by Berenberg on Thursday, May 12. The rating was upgraded by Suntrust Robinson on Wednesday, November 25 to “Neutral”. The rating was initiated by Societe Generale with “Hold” on Wednesday, April 6. The firm has “Neutral” rating by Goldman Sachs given on Monday, April 18. BMO Capital Markets downgraded Pfizer Inc. (NYSE:PFE) on Wednesday, November 2 to “Market Perform” rating. Jefferies maintained it with “Buy” rating and $41.50 target price in Thursday, July 14 report. Jefferies maintained it with “Buy” rating and $39 target price in Tuesday, September 13 report. The stock of Pfizer Inc. (NYSE:PFE) has “Buy” rating given on Friday, August 14 by Piper Jaffray. Jefferies maintained the shares of PFE in a report on Monday, June 20 with “Buy” rating. Credit Suisse maintained the shares of PFE in a report on Monday, May 9 with “Outperform” rating.

PFE Company Profile

Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research global biopharmaceutical company. The Firm is engaged in discovering, developing and manufacturing of healthcare products. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. The Company’s biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. The Company’s biotechnology products include BeneFIX, ReFacto and Xyntha.

More important recent Pfizer Inc. (NYSE:PFE) news were published by: Bloomberg.com which released: “Pfizer Ends Cholesterol Drug Trials as Earnings Fall Short” on November 01, 2016, also Fool.com published article titled: “Better Buy: Gilead Sciences Inc. vs. Pfizer Inc.”, Profitconfidential.com published: “Pfizer Inc. (NYSE:PFE): Why Is PFE Stock Going Nuts Today?” on November 09, 2016. More interesting news about Pfizer Inc. (NYSE:PFE) was released by: Businesswire.com and their article: “Pfizer Announces Pricing of Tender Offer for Any and All of its 6.200% Senior …” with publication date: November 16, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Winifred Garcia


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>